AAPL321.20-7.02 (-2.14%) ▼|ABBV256.86-3.35 (-1.29%) ▼|ABT109.40+0.61 (+0.56%) ▲|ACN188.41-4.71 (-2.44%) ▼|ADBE268.36-17.40 (-6.09%) ▼|AMAT452.33+16.42 (+3.77%) ▲|AMD474.25+18.09 (+3.97%) ▲|AMGN436.50-7.62 (-1.72%) ▼|AMT176.21-1.54 (-0.87%) ▼|AMZN257.12-1.79 (-0.69%) ▼|AVGO354.76-2.40 (-0.67%) ▼|AXP327.37-2.45 (-0.74%) ▼|BA210.35-0.17 (-0.08%) ▼|BAC62.69-0.04 (-0.06%) ▼|BKNG193.83-1.30 (-0.67%) ▼|BLK1,121.01-5.14 (-0.46%) ▼|BMY66.66-1.44 (-2.11%) ▼|BNY165.49+1.16 (+0.71%) ▲|BRK-B506.14-1.99 (-0.39%) ▼|C137.88-0.26 (-0.19%) ▼|CAT810.38+10.24 (+1.28%) ▲|CL89.25-0.84 (-0.93%) ▼|CMCSA26.57-0.09 (-0.32%) ▼|COF219.98-0.53 (-0.24%) ▼|COP134.84-0.88 (-0.65%) ▼|COST917.18-8.23 (-0.89%) ▼|CRM260.81-3.62 (-1.37%) ▼|CSCO109.41+0.80 (+0.74%) ▲|CVS97.30+0.10 (+0.10%) ▲|CVX209.04-2.28 (-1.08%) ▼|DE696.31+1.90 (+0.27%) ▲|DHR206.74-4.30 (-2.04%) ▼|DIS105.69-1.48 (-1.38%) ▼|DUK120.43-0.97 (-0.80%) ▼|EMR153.27+3.06 (+2.04%) ▲|FDX321.74-2.58 (-0.79%) ▼|GD359.50-6.38 (-1.74%) ▼|GE335.57+2.09 (+0.63%) ▲|GEV941.37-0.48 (-0.05%) ▼|GILD150.61-0.61 (-0.40%) ▼|GM87.16+0.12 (+0.14%) ▲|GOOG335.28-3.80 (-1.12%) ▼|GOOGL338.62-3.64 (-1.06%) ▼|GS1,036.81-1.12 (-0.11%) ▼|HD320.54+2.47 (+0.78%) ▲|HON208.02+0.39 (+0.19%) ▲|IBM234.97+0.26 (+0.11%) ▲|INTC94.88+3.21 (+3.50%) ▲|INTU332.99-11.32 (-3.29%) ▼|ISRG364.16-5.67 (-1.53%) ▼|JNJ275.91-2.52 (-0.91%) ▼|JPM358.61-3.45 (-0.95%) ▼|KO88.01-0.81 (-0.91%) ▼|LIN479.26-2.93 (-0.61%) ▼|LLY1,144.43-15.17 (-1.31%) ▼|LMT526.07-6.88 (-1.29%) ▼|LOW203.87+1.97 (+0.97%) ▲|LRCX303.24+10.58 (+3.61%) ▲|MA582.37-3.34 (-0.57%) ▼|MCD256.84-2.80 (-1.08%) ▼|MDLZ61.48+0.03 (+0.04%) ▲|MDT94.37+1.27 (+1.36%) ▲|META609.53-1.15 (-0.19%) ▼|MMM168.25-0.07 (-0.04%) ▼|MO68.83-0.67 (-0.96%) ▼|MRK150.36-1.99 (-1.30%) ▼|MS217.09-0.06 (-0.03%) ▼|MSFT501.03-9.10 (-1.78%) ▼|MU1,000.66+42.50 (+4.44%) ▲|NEE83.46-0.61 (-0.72%) ▼|NFLX78.97-3.71 (-4.48%) ▼|NKE38.38-0.39 (-1.01%) ▼|NOW141.53-4.06 (-2.79%) ▼|NVDA230.82+2.37 (+1.04%) ▲|ORCL157.65+3.61 (+2.34%) ▲|PEP137.75-0.79 (-0.57%) ▼|PFE28.51-0.30 (-1.04%) ▼|PG146.43-0.49 (-0.33%) ▼|PLTR174.57-7.96 (-4.36%) ▼|PM182.70-3.47 (-1.86%) ▼|QCOM167.91-0.66 (-0.39%) ▼|RTX200.36-1.78 (-0.88%) ▼|SBUX105.60-0.22 (-0.21%) ▼|SCHW109.23-1.15 (-1.04%) ▼|SO87.96-0.81 (-0.91%) ▼|SPG210.99-0.54 (-0.25%) ▼|T25.93-0.27 (-1.01%) ▼|TMO612.73-5.70 (-0.92%) ▼|TMUS182.20-5.82 (-3.10%) ▼|TSLA352.45-23.92 (-6.35%) ▼|TXN257.92+4.09 (+1.61%) ▲|UBER76.08+0.12 (+0.16%) ▲|UNH397.52-3.42 (-0.85%) ▼|UNP290.61+1.46 (+0.50%) ▲|UPS102.70-0.80 (-0.77%) ▼|USB63.56+0.03 (+0.05%) ▲|V375.95-2.80 (-0.74%) ▼|VZ50.30-0.29 (-0.57%) ▼|WFC89.72+0.53 (+0.59%) ▲|WMT107.32-1.10 (-1.01%) ▼|XOM160.45-1.76 (-1.09%) ▼|AAPL321.20-7.02 (-2.14%) ▼|ABBV256.86-3.35 (-1.29%) ▼|ABT109.40+0.61 (+0.56%) ▲|ACN188.41-4.71 (-2.44%) ▼|ADBE268.36-17.40 (-6.09%) ▼|AMAT452.33+16.42 (+3.77%) ▲|AMD474.25+18.09 (+3.97%) ▲|AMGN436.50-7.62 (-1.72%) ▼|AMT176.21-1.54 (-0.87%) ▼|AMZN257.12-1.79 (-0.69%) ▼|AVGO354.76-2.40 (-0.67%) ▼|AXP327.37-2.45 (-0.74%) ▼|BA210.35-0.17 (-0.08%) ▼|BAC62.69-0.04 (-0.06%) ▼|BKNG193.83-1.30 (-0.67%) ▼|BLK1,121.01-5.14 (-0.46%) ▼|BMY66.66-1.44 (-2.11%) ▼|BNY165.49+1.16 (+0.71%) ▲|BRK-B506.14-1.99 (-0.39%) ▼|C137.88-0.26 (-0.19%) ▼|CAT810.38+10.24 (+1.28%) ▲|CL89.25-0.84 (-0.93%) ▼|CMCSA26.57-0.09 (-0.32%) ▼|COF219.98-0.53 (-0.24%) ▼|COP134.84-0.88 (-0.65%) ▼|COST917.18-8.23 (-0.89%) ▼|CRM260.81-3.62 (-1.37%) ▼|CSCO109.41+0.80 (+0.74%) ▲|CVS97.30+0.10 (+0.10%) ▲|CVX209.04-2.28 (-1.08%) ▼|DE696.31+1.90 (+0.27%) ▲|DHR206.74-4.30 (-2.04%) ▼|DIS105.69-1.48 (-1.38%) ▼|DUK120.43-0.97 (-0.80%) ▼|EMR153.27+3.06 (+2.04%) ▲|FDX321.74-2.58 (-0.79%) ▼|GD359.50-6.38 (-1.74%) ▼|GE335.57+2.09 (+0.63%) ▲|GEV941.37-0.48 (-0.05%) ▼|GILD150.61-0.61 (-0.40%) ▼|GM87.16+0.12 (+0.14%) ▲|GOOG335.28-3.80 (-1.12%) ▼|GOOGL338.62-3.64 (-1.06%) ▼|GS1,036.81-1.12 (-0.11%) ▼|HD320.54+2.47 (+0.78%) ▲|HON208.02+0.39 (+0.19%) ▲|IBM234.97+0.26 (+0.11%) ▲|INTC94.88+3.21 (+3.50%) ▲|INTU332.99-11.32 (-3.29%) ▼|ISRG364.16-5.67 (-1.53%) ▼|JNJ275.91-2.52 (-0.91%) ▼|JPM358.61-3.45 (-0.95%) ▼|KO88.01-0.81 (-0.91%) ▼|LIN479.26-2.93 (-0.61%) ▼|LLY1,144.43-15.17 (-1.31%) ▼|LMT526.07-6.88 (-1.29%) ▼|LOW203.87+1.97 (+0.97%) ▲|LRCX303.24+10.58 (+3.61%) ▲|MA582.37-3.34 (-0.57%) ▼|MCD256.84-2.80 (-1.08%) ▼|MDLZ61.48+0.03 (+0.04%) ▲|MDT94.37+1.27 (+1.36%) ▲|META609.53-1.15 (-0.19%) ▼|MMM168.25-0.07 (-0.04%) ▼|MO68.83-0.67 (-0.96%) ▼|MRK150.36-1.99 (-1.30%) ▼|MS217.09-0.06 (-0.03%) ▼|MSFT501.03-9.10 (-1.78%) ▼|MU1,000.66+42.50 (+4.44%) ▲|NEE83.46-0.61 (-0.72%) ▼|NFLX78.97-3.71 (-4.48%) ▼|NKE38.38-0.39 (-1.01%) ▼|NOW141.53-4.06 (-2.79%) ▼|NVDA230.82+2.37 (+1.04%) ▲|ORCL157.65+3.61 (+2.34%) ▲|PEP137.75-0.79 (-0.57%) ▼|PFE28.51-0.30 (-1.04%) ▼|PG146.43-0.49 (-0.33%) ▼|PLTR174.57-7.96 (-4.36%) ▼|PM182.70-3.47 (-1.86%) ▼|QCOM167.91-0.66 (-0.39%) ▼|RTX200.36-1.78 (-0.88%) ▼|SBUX105.60-0.22 (-0.21%) ▼|SCHW109.23-1.15 (-1.04%) ▼|SO87.96-0.81 (-0.91%) ▼|SPG210.99-0.54 (-0.25%) ▼|T25.93-0.27 (-1.01%) ▼|TMO612.73-5.70 (-0.92%) ▼|TMUS182.20-5.82 (-3.10%) ▼|TSLA352.45-23.92 (-6.35%) ▼|TXN257.92+4.09 (+1.61%) ▲|UBER76.08+0.12 (+0.16%) ▲|UNH397.52-3.42 (-0.85%) ▼|UNP290.61+1.46 (+0.50%) ▲|UPS102.70-0.80 (-0.77%) ▼|USB63.56+0.03 (+0.05%) ▲|V375.95-2.80 (-0.74%) ▼|VZ50.30-0.29 (-0.57%) ▼|WFC89.72+0.53 (+0.59%) ▲|WMT107.32-1.10 (-1.01%) ▼|XOM160.45-1.76 (-1.09%) ▼|
28.3 C
New York
Friday, September 4, 2026

Tag: drug

newssourceFORcompanyinformationcontent1releasesmarket

Global Digital Health Market Poised for Robust Growth at a CAGR of ~18% by 2032 Amid Rising Demand for Remote Care| DelveInsight

The digital health market is experiencing robust growth, driven by increasing adoption of telemedicine, wearable devices, and AI-powered health solutions. Rising healthcare costs and...

Tumor-Infiltrating Lymphocyte Therapy Market Gains Momentum with Expanding Oncology Applications | DelveInsight

Over the last ten years, cell-based immunotherapy has emerged as a promising approach for treating solid tumors. Several companies, including Iovance Biotherapeutics, Obsidian Therapeutics,...

Tumor-Infiltrating Lymphocyte Therapy Market Gains Momentum with Expanding Oncology Applications | DelveInsight

Over the last ten years, cell-based immunotherapy has emerged as a promising approach for treating solid tumors. Several companies, including Iovance Biotherapeutics, Obsidian Therapeutics,...

Eupraxia Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update

VICTORIA, British Columbia, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, today announced its financial results for the second quarter of 2025 and provided a business update. All dollar values are in U.S. dollars unless stated otherwise.

vTv Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

•   First study participant randomized in Phase 3 CATT1 trial evaluating cadisegliatin for the treatment of type 1 diabetes with data expected in second half of 2026

Armata Pharmaceuticals Announces Second Quarter 2025 Results and Provides Corporate Update

Entered into secured credit agreement with Innoviva for $15 million maturing in 2029 Announced positive topline results from the Phase 1b/2a diSArm trial for AP-SA02 LOS...

Theravance Biopharma, Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate Update

YUPELRI® (revefenacin) net sales of $66.3 million, recognized by Viatris, increased 22% year-over-year1Pivotal Phase 3 CYPRESS study enrollment on track to complete by late...

Caris Life Sciences Reports Second Quarter 2025 Financial Results

IRVING, Texas, Aug. 12, 2025 /PRNewswire/ -- Caris Life Sciences, Inc. (Nasdaq: CAI), a leading, patient-centric, next-generation AI TechBio company, today reported financial results...

AbbVie Announces $195 Million Investment to Expand Active Pharmaceutical Ingredient Manufacturing in the U.S.

New $195 million facility will further enhance AbbVie's active pharmaceutical ingredient (API) production capacity and capabilities in the U.S.Expansion is part of AbbVie's previously announced commitment...

FDA Approves BRINSUPRI™ (brensocatib) as the First and Only Treatment for Non-Cystic Fibrosis Bronchiectasis, a Serious, Chronic Lung Disease

— Approximately 500,000 U.S. Patients Are Diagnosed with Non-Cystic Fibrosis Bronchiectasis (NCFB), a Progressive Disease That Can Lead to Permanent Lung Damage — — BRINSUPRI 10...

5 Pew-Stewart Scholars Selected to Pursue Pioneering Cancer Research

PHILADELPHIA, Aug. 12, 2025 /PRNewswire/ -- The Pew Charitable Trusts and the Alexander and Margaret Stewart Trust announced today the 2025 class of the...

Myra Vision Secures FDA Approval to Initiate US IDE Study in Glaucoma

The ADAPT study will evaluate the safety and effectiveness of the company's Calibreye™ Titratable Glaucoma Therapy™ (TGT) Surgical System CAMPBELL, Calif., Aug. 12, 2025 /PRNewswire/...

Women’s Health Collective Canada and Shoppers Foundation for Women’s Health™ Deepen Partnership with $1 Million Commitment to Health Research and Care

Shoppers Foundation for Women’s Health makes a $1 million investment in health research with Women's Health Collective Canada.

SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sarepta Therapeutics

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Sarepta To Contact Him Directly To Discuss Their Options

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsDrug

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers